Outcomes of Surface Replacement Arthroplasty in Metacarpophalangeal Joints Affected by Noninflammatory Arthritis.

MCP joint metacarpophalangeal joint arthritis metacarpophalangeal joint arthroplasty noninflammatory arthritis surface replacement arthroplasty

Journal

Hand (New York, N.Y.)
ISSN: 1558-9455
Titre abrégé: Hand (N Y)
Pays: United States
ID NLM: 101264149

Informations de publication

Date de publication:
05 2023
Historique:
pmc-release: 01 05 2024
medline: 1 5 2023
pubmed: 1 8 2021
entrez: 31 7 2021
Statut: ppublish

Résumé

The purpose of this study was to investigate the outcomes of surface replacement arthroplasty (SRA) for noninflammatory arthritis of the metacarpophalangeal (MCP) joint. Records from 20 SRAs performed between 1995 and 2017 in 17 patients with noninflammatory arthritis affecting the MCP joint were retrospectively reviewed. The mean follow up was 6.6 years. Three arthroplasties (15%) underwent 4 revision operations. The 2-, 5-, 10-, and 15-year rates of survival from surface replacement implant revision were 90%, 90%, 79%, and 79%, respectively. Major complications occurring in revised joints included arthrodesis (n = 1) and amputation (n = 1). The overall reoperation rate was 35%. The 2-, 5-, 10-, and 15-year rates of overall reoperation-free survival were 75%, 69%, 60%, and 60%, respectively. Pain ratings and MCP arc of motion significantly improved following arthroplasty. Metacarpophalangeal SRA for noninflammatory arthritis can improve arc of motion and pain. Revision is uncommon; however, 1 in 3 joints requires reoperation.

Sections du résumé

BACKGROUND
The purpose of this study was to investigate the outcomes of surface replacement arthroplasty (SRA) for noninflammatory arthritis of the metacarpophalangeal (MCP) joint.
METHODS
Records from 20 SRAs performed between 1995 and 2017 in 17 patients with noninflammatory arthritis affecting the MCP joint were retrospectively reviewed. The mean follow up was 6.6 years.
RESULTS
Three arthroplasties (15%) underwent 4 revision operations. The 2-, 5-, 10-, and 15-year rates of survival from surface replacement implant revision were 90%, 90%, 79%, and 79%, respectively. Major complications occurring in revised joints included arthrodesis (n = 1) and amputation (n = 1). The overall reoperation rate was 35%. The 2-, 5-, 10-, and 15-year rates of overall reoperation-free survival were 75%, 69%, 60%, and 60%, respectively.
CONCLUSIONS
Pain ratings and MCP arc of motion significantly improved following arthroplasty. Metacarpophalangeal SRA for noninflammatory arthritis can improve arc of motion and pain. Revision is uncommon; however, 1 in 3 joints requires reoperation.

Identifiants

pubmed: 34330177
doi: 10.1177/15589447211028917
pmc: PMC10152535
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

463-468

Références

J Hand Surg Am. 2010 Jan;35(1):44-51
pubmed: 20117307
Hand (N Y). 2022 Mar;17(2):271-277
pubmed: 32486855
J Bone Joint Surg Am. 1984 Mar;66(3):365-70
pubmed: 6699052
J Bone Joint Surg Am. 2012 Jun 20;94(12):1120-8
pubmed: 22717831
Hand Clin. 2006 May;22(2):183-93
pubmed: 16701131
J Hand Surg Am. 2011 Feb;36(2):345-53
pubmed: 21276901
J Hand Surg Am. 2005 Jul;30(4):667-72
pubmed: 16039355
Scand J Plast Reconstr Surg Hand Surg. 1999 Dec;33(4):433-8
pubmed: 10614754
Plast Reconstr Surg. 2014 Dec;134(6):1260-1268
pubmed: 25415093
J Hand Surg Am. 2013 Mar;38(3):537-43
pubmed: 23337462
J Hand Surg Am. 2000 Sep;25(5):796-816
pubmed: 11040295
J Bone Joint Surg Br. 2004 Sep;86(7):1002-6
pubmed: 15446527
J Hand Surg Am. 2011 Jun;36(6):1015-21
pubmed: 21549521
J Hand Surg Am. 2008 Nov;33(9):1565.e1-11
pubmed: 18984339
J Hand Surg Eur Vol. 2018 Dec;43(10):1076-1082
pubmed: 29848135
J Rheumatol. 2010 Mar;37(3):544-9
pubmed: 20080920
J Hand Surg Am. 2015 Oct;40(10):1956-62
pubmed: 26281977
J Rheumatol. 2000 Jun;27(6):1395-402
pubmed: 10852260
Clin Orthop Relat Res. 1997 Sep;(342):16-21
pubmed: 9308519
Hand Surg. 2002 Jul;7(1):139-46
pubmed: 12365055
Instr Course Lect. 1989;38:73-102
pubmed: 2649594
J Hand Surg Am. 2009 May-Jun;34(5):815-23
pubmed: 19410984
J Hand Surg Eur Vol. 2014 Jul;39(6):575-81
pubmed: 24272927
Acta Orthop Scand. 1994 Aug;65(4):430-1
pubmed: 7976291
J Bone Joint Surg Am. 1972 Apr;54(3):435-55
pubmed: 5055146
J Bone Joint Surg Am. 2003 Oct;85(10):1869-78
pubmed: 14563791
J Hand Surg Am. 1997 Mar;22(2):286-98
pubmed: 9195428
J Hand Surg Am. 1996 Sep;21(5):813-8
pubmed: 8891979
J Hand Surg Am. 1986 May;11(3):333-9
pubmed: 3711605

Auteurs

Matthew R Claxton (MR)

Mayo Clinic College of Medicine & Science, Rochester, MN, USA.

Eric R Wagner (ER)

Emory University, Atlanta, GA, USA.

Marco Rizzo (M)

Mayo Clinic, Rochester, MN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH